scholarly journals Monitoring magnesium efflux cyclic AMP-induced in HL60 cells by using a new hydroxyquinoline fluorescent chemosensor

Author(s):  
Chiara Marraccini ◽  
Azzurra Sargenti ◽  
Lucia Merolle ◽  
Concettina Cappadone ◽  
Giovanna Farruggia ◽  
...  

Cellular homeostasis of magnesium is still unclear. Several studies documented the occurrence of fluxes of magnesium across the plasmamembrane within minutes from the application of metabolic or hormonal stimuli. These fluxes, however, result in limited variation of free Mg2+ intracellular concentration and large changes in total Mg content. It has been reported that a stimulation with cyclic AMP caused a movement of total magnesium within 10 min after treatment in cardiomyocytes. In this study we tested this hypothesis in HL60 leukemic cells, not excitable but highly proliferating cell model. We evaluated Mg flux by DCHQ5, the phenyl-derivative of hydroxyquinoline fluorescent probe family. We observed a drastic decrease of intracellular total magnesium in the first 3 min. We also verified that at least 10% of the total intracellular amount of magnesium moved in the supernatant of stimulated cells.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 883-883 ◽  
Author(s):  
TzuChieh Ho ◽  
Mark W LaMere ◽  
Kristen O'Dwyer ◽  
Jason H. Mendler ◽  
Jane L. Liesveld ◽  
...  

Abstract Acute Myelogenous Leukemia (AML) is a disease that clinically evolves over time as many patients who are responsive to therapy upfront acquire resistance to the same agents when applied in the relapse setting. The stem cell model for AML has been invoked to explain primary resistance to standard therapy; the leukemia stem cell (LSC) population representing a therapy-refractory reservoir for relapse. There have been no prospective efforts to formally assess the evolution of the LSC population during patients’ clinical course. We performed a prospective characterization of specimens from a well-defined cohort of patients with AML at diagnosis and relapse to assess the frequency and phenotype of functionally defined LSCs. Methods Primary bone marrow and peripheral blood samples were collected on IRB approved protocols from patients with newly diagnosed AML undergoing induction therapy. Twenty-five patients who relapsed after achieving a complete remission were selected for further study. Screening studies identified seven patients whose pre-therapy samples demonstrated sustained engraftment of NSG mice following transplantation. Pre-therapy and post-relapse LSC frequencies were assessed using xenotransplantation limiting dilution analyses (LDA). We assessed the frequencies of CD45RA, CD32, TIM-3, CD96, CD47, and CD97 expressing populations that have been previously published to possess LSC activity. Functionally validated pre-therapy and post-relapse LSC populations were identified using fluorescent labeled cell sorting and NSG xenotransplantation. LSC activity was confirmed for each population using secondary xenotransplantation. Gene expression analysis of highly enriched LSC populations from pre-therapy and post-relapse samples was performed using ABI TILDA qPCR analyses following pre-amplification. Results We demonstrated by LDA an 8 to 42-fold increase in LSC frequency between diagnosis and relapse in paired primary patient samples. The increase in LSC activity was not associated with an increase in frequency for phenotypically-defined populations previously reported to possess LSC activity. Rather, we found that LSC activity expanded at relapse to immunophenotypic populations of leukemic cells that did not possess LSC activity prior to treatment. Moreover, in all patients, the number of phenotypically distinct LSC populations (as defined by CD34 and CD38 or CD32 and CD38) detectable at relapse was dramatically expanded. Further, while the majority of the LSC populations’ gene expression profile remained stable between diagnosis and relapse, a subset of genes were enriched in defined LSC populations at relapse including IL3-receptor alpha and IL1-RAP, both previously demonstrated to play a role in LSC biology. Conclusions This study is the first to characterize the natural evolution of LSCs in vivo following treatment and relapse. We demonstrate an increase in LSC activity and greatly increased phenotypic diversity of the LSC population, suggesting a loss of hierarchical organization following relapse. These findings demonstrate that treatment of AML patients with conventional chemotherapy regimens can promote quantitative and qualitative expansion of the LSC compartment. Further, the data indicate that surface antigen immune-phenotype is not predictive of function in relapse and suggest a major limitation to efforts targeting specific surface antigens in the relapse setting. Understanding the mechanisms by which LSC expansion occurs and how to target it will likely improve our currently poor treatment options for patients who relapse. Disclosures: Becker: Millenium: Research Funding.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2457-2457
Author(s):  
Hong (Jenny) Gao ◽  
Xiaoming Wu ◽  
Zhenglun (Jerry) Zhu

Abstract Abstract 2457 Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, representing about a third of all pediatric cancers. Despite significant progress in ALL treatment over the past decades, relapse occurs in about 20% cases, which are often resistant to conventional chemotherapy. The canonical Wnt/b-catenin signaling has been implicated in pathogenesis of ALL, and has been a target of intensive investigation for its potential application in cancer prevention and treatment. During our recent studies, using methods of reverse genetics and developmental modeling of Xenopus embryogenesis, we identified VentX as a novel Wnt antagonist and a putative tumor suppressor in lymphocyte leukemia. On the basis of our prior findings that VentX inhibit proliferation of lymphoblastic leukemic cells, our current studies are designed to explore the potential role of VentX as a novel therapeutic target of ALL and its underlying mechanisms. Using lymphoblastic cell model and real-time RT-PCR technique, we found that VentX expression can be induced by chemotherapeutic agents. We found that elevated expression of VentX caused a senescence phenotype in lymphoblastic leukemic cells and importantly, down-regulation of VentX expression by RNA interference technique led to strong attenuation of the cytotoxic effects of chemotherapeutic agents. Mechanistically, we found that VentX binds to the promoter and p53 and p16 and transactivates the p53/p21 and the p16/pRb senescence pathways, which have been implicated in pathogenesis of ALL. We found further that VentX control these two senescence pathways in primary B lymphocytes and that inactivation of both pathways rather than one is required to abolish the inhibitory effects of VentX on the proliferation of lymphoblastic leukemia cells. In summary, the results of our investigation suggest that VentX is a novel therapeutic target of ALL. We found that VentX poised as a pivotal link between the oncogenic Wnt signaling pathway and the tumor suppressing senescence pathway. Given the implications of Wnt and senescence pathway in leukemia stem cells, a resource of chemo-resistance and relapse, targeting VentX may present novel opportunities for managing refractory cases of ALL and the eventual cure of the diseases. Disclosures: No relevant conflicts of interest to declare.


1991 ◽  
Vol 15 (11) ◽  
pp. 965-974 ◽  
Author(s):  
Monica Giordano ◽  
Marco Danova ◽  
Carlo Pellicciari ◽  
George D. Wilson ◽  
Giuliano Mazzini ◽  
...  

Blood ◽  
2009 ◽  
Vol 113 (17) ◽  
pp. 4016-4026 ◽  
Author(s):  
Cynthia A. Pise-Masison ◽  
Michael Radonovich ◽  
Kathleen Dohoney ◽  
John C. Morris ◽  
Deirdre O'Mahony ◽  
...  

Abstract Adult T-cell leukemia/lymphoma (ATL) is an aggressive and fatal disease. We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays. Using the BRB array program, we identified genes differentially expressed in leukemia cells compared with normal lymphocytes. Several unique genes were identified that were overexpressed in leukemic cells, including TNFSF11, RGS13, MAFb, CSPG2, C/EBP-α, and TCF4; 200 of the most highly overexpressed ATL genes were analyzed by the Pathway Studio, version 4.0 program. ATL leukemia cells were characterized by an increase in genes linked to “central” genes CDC2/cyclin B1, SYK/LYN, proliferating cell nuclear antigen, and BIRC5. Because of its potential therapeutic importance, we focused our studies on the regulation and function of BIRC5, whose expression was increased in 13 of 14 leukemia samples. TCF4 reporter assays and transfection of DN-TCF4 demonstrated that TCF4 regulates BIRC5 gene expression. Functionally, transfection of ATL cells with BIRC5 shRNA decreased BIRC5 expression and cell viability 80%. Clinical treatment of ATL patients with Zenapax or bortezomib decreased BIRC5 expression and cell viability. These experiments represent the first direct experimental evidence that BIRC5 plays an important role in ATL cell viability and provides important insight into ATL genesis and potential targeted therapies.


2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Sara Castiglioni ◽  
Alessandra Cazzaniga ◽  
Valentina Trapani ◽  
Concettina Cappadone ◽  
Giovanna Farruggia ◽  
...  

Abstract Neoplastic cells accumulate magnesium, an event which provides selective advantages and is frequently associated with TRPM7overexpression. Little is known about magnesium homeostasis in drug-resistant cancer cells. Therefore, we used the colon cancer LoVo cell model and compared doxorubicin-resistant to sensitive cells. In resistant cells the concentration of total magnesium is higher while its influx capacity is lower than in sensitive cells. Accordingly, resistant cells express lower amounts of the TRPM6 and 7, both involved in magnesium transport. While decreased TRPM6 levels are due to transcriptional regulation, post-transcriptional events are involved in reducing the amounts of TRPM7. Indeed, the calpain inhibitor calpeptin markedly increases the levels of TRPM7 in resistant cells. In doxorubicin-sensitive cells, silencing TRPM7 shifts the phenotype to one more similar to resistant cells, since in these cells silencing TRPM7 significantly decreases the influx of magnesium, increases its intracellular concentration and increases resistance to doxorubicin. On the other hand, calpain inhibition upregulates TRPM7, decreases intracellular magnesium and enhances the sensitivity to doxorubicin of resistant LoVo cells. We conclude that in LoVo cells drug resistance is associated with alteration of magnesium homeostasis through modulation of TRPM7. Our data suggest that TRPM7 expression may be an additional undisclosed player in chemoresistance.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3365-3365
Author(s):  
Djamel Aggoune ◽  
Angelina Bertrand ◽  
Marie Laure Bonnet ◽  
Amelie Le Corf ◽  
Sandrine Girerd ◽  
...  

Abstract Abstract 3365 Recent data suggest that the occurrence of T315I mutation, due in part to genetic instability induced by BCR-ABL, confers to the hematopoietic cells acquiring this mutation an additional genetic instability. Specific signalling pathways induced by T315I mutation could be at the origin of this phenomenon. As T315I substitution arises as a subclone of BCR-ABL-expressing cells, it is very difficult to study the specific effects of the putative mutational effect in primary CML cells. To determine if an additional genetic instability is induced in the presence of T315I, we have used the human UT7 cell model in which we have stably introduced BCR-ABL and BCR-ABL T315I using retroviral vectors. Western blot analysis showed that BCR-ABL protein levels were equivalent in both cell lines. To determine the global genomic instability phenomenon induced by BCR-ABL we have performed a mutator phenotype assay using the detection of HPRT mutants in the presence of 6-Thioguanine (6-TG) in control, wild-type BCR-ABL and BCR-ABL T315I-expressing UT7 cells in methycellulose assays. 6-TG resistant HPRT mutant colonies were quantified 3–4 weeks after initial seeding. The same cells were also used to quantify the baseline levels of &Ugr;-H2AX phosphorylation, indicative of double strand breaks (DSB). In addition, the same experiments were performed after the co-culture of the cells in the presence of a hematopoietic niche. Results: In the experimental conditions used, 6-TG resistant colonies were identified only in T315I-mutated cells, with a frequency of 7.9 10−6. The individually plucked HPRT mutants grew in liquid cultures in the presence of 6-TG, confirming the presence of a 6-TG resistance. Interestingly, the co-culture in the presence of MS-5 cell line for 3 days, increased the mutator phenotype (12. 10−6). The analysis of baseline g-H2AX levels showed a clear increase of &Ugr;-H2AX phosphorylation in UT7-T315I cells as compared to UT7-BCR-ABL which showed slightly higher levels as compared to control. To determine the long-term influence of Imatinib in the mutator phenotype, we cultured T315I cells in the presence of IM 1 microM for 7, 21 and 36 days followed by a mutator assay. The frequency of mutator phenotype was found to be stable, varying from 4.4 10−6 at day 7 to 5.24 10−6 at day 36 in the presence of IM. To determine the influence of the niche on the genomic instability, we have treated the UT7, UT7-BCR-ABL and UT7-T315I cells with mitomycin C (MMC) for 6 and 18 hours in the absence or in the presence of MS5 cells, followed by quantification of &Ugr;-H2AX levels at day+3. in these conditions, MMC induced '-H2AX levels were higher in T315I-mutated cells as compared to UT7 and the co-culture with MS-5 cells reduced this phenomenon. Thus, T315I mutation confers higher levels of DSB in steady state and increases the mutator phenotype of BCR-ABL-expressing cells. The co-culture in the presence of the niche reduces DSB but further increases the frequency of mutator phenotype, suggesting that the niche is not the major factor of genetic instability but stimulates the self-renewal of T315I-mutation bearing leukemic cells. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document